Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
1d
Zacks Investment Research on MSNHow to Play SRPT Stock After Patient Death Post DMD Therapy InfusionShares of Sarepta Therapeutics SRPT plunged nearly 24% last week after the company reported the death of a patient following ...
A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the ...
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare musc ...
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results